Last reviewed · How we verify
Placebo + anti-H1
Placebo combined with an anti-H1 antihistamine blocks histamine H1 receptors to reduce allergic and inflammatory responses.
Placebo combined with an anti-H1 antihistamine blocks histamine H1 receptors to reduce allergic and inflammatory responses. Used for Allergic conditions (specific indication not detailed in provided information).
At a glance
| Generic name | Placebo + anti-H1 |
|---|---|
| Also known as | Placebo of methetrexate + anti-H1 |
| Sponsor | University Hospital, Tours |
| Drug class | H1-receptor antagonist (antihistamine) |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology / Allergy |
| Phase | Phase 3 |
Mechanism of action
Anti-H1 antihistamines competitively antagonize histamine at H1 receptors, which are responsible for allergic symptoms such as itching, urticaria, and angioedema. The placebo component serves as a control in this phase 3 trial design. Together, this combination is used to evaluate the efficacy of anti-H1 therapy in allergic conditions.
Approved indications
- Allergic conditions (specific indication not detailed in provided information)
Common side effects
- Drowsiness
- Headache
- Dry mouth
Key clinical trials
- Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension. (PHASE3)
- Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment (PHASE2)
- Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria (PHASE3)
- Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria (PHASE3)
- A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines. (PHASE3)
- Trial of JYB1904 in Chronic Spontaneous Urticaria. (PHASE2)
- Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines (PHASE3)
- Cholinergic Urticaria - Efficacy of Dupilumab (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo + anti-H1 CI brief — competitive landscape report
- Placebo + anti-H1 updates RSS · CI watch RSS
- University Hospital, Tours portfolio CI